Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) in platform presentations, as well as present six posters, including the first data on its NS5A inhibitor.
Media Contact
Tracy Sorrentino
(847) 937-8712
tracy.sorrentino@abbott.com